NCT07748039RecruitingPhase 3
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain. The TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT. Participants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1440 (estimated)
- First submitted
- 26 Jul 2026
- Start date
- 16 Oct 2026
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Yongjun Wang
- Diseases
- Stroke
- NCT number
- NCT07748039
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1440
- From 16 Oct 2026 to the primary completion date, 1 Mar 2029
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Intracranial hemorrhage (ICH) identified by CT or MRI
- mRS \> 2 before stroke onset.
- Secondary transfer from a primary stroke center
- Any terminal illness such that patient would not be expected to survive more than one year
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study
Other
- Rapidly improving symptoms at the discretion of the investigator
- Massive cerebral infarction (infarct size greater than one-third of the blood middle cerebral artery supply area) suggested by CT.
- Known contraindication to imaging with contrast agents
- Planned adjunct intra-arterial (IA) thrombolysis during or after endovascular treatment (EVT).
- Pregnant women
Who the study is looking for
- Patients with acute ischemic stroke presenting within 4.5 hours of symptom onset who are eligible for intravenous thrombolytic therapy. A baseline non-contrast CT or MRI is required for screening.
- Large vessel occlusion on computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) of the intracranial carotid artery (ICA) or middle cerebral artery (MCA) M1
- Age ⩾ 18 years at the time of signing the informed consent form
- ASPECTS 6-10
- Informed consent from the patients or their legal representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital, Capital Medical Universiity Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Rizhao Hospital of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Rizhao | China | Not yet recruiting |
| Zhongnan Hospital of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Not yet recruiting |
| Xiangtan Central Hospital Coordinator of this site? Confirm its status | Xiangtan | China | Not yet recruiting |
| Ya 'an People's Hospital Coordinator of this site? Confirm its status | Ya'an | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.